Table 3:

Primary and secondary MRI outcomes in patients with MS with and without comorbiditiesa

Patients with MS with Comorbidities (n = 241)Patients with MS without Comorbidities (n = 574)P Value
Primary MRI outcomes
    T2-LV15.7 (15.5)15.3 (18.2).943
    T1-LV2.8 (4.7)2.6 (4.7).955
    Gd-LV0.08 (0.3)0.1 (0.4).992
    NBV1451.1 (97.3)1481 (86.4)<.001b
    MTR-NABT34.1 (5.1)35.3 (5).01b
Secondary MRI outcomes
    NGMV722.8 (86.9)747.9 (81.5).01b
    NWMV728.3 (86.7)732.6 (64).311
    NCV537.1 (67.3)557.6 (62.8)<.001b
    NLVV47.5 (20.6)45.3 (20.5).528
    MTR-NAGM31.1 (5.5)32.3 (5.1).045b
    MTR-NAWM37.1 (5.3)38.1 (4.9).105
    MTR-T2-LV32.3 (4.8)32.8 (5.1).650
    MD × 1031.26 (0.29)1.22 (0.22).136
  • Note:—Gd indicates gadolinium; NWMV, normalized white matter volume; NLVV, normalized lateral ventricle volume; NAGM, normal-appearing gray matter; NBV, normalized brain volume; NGMV, normalized gray matter volume; NCV, normalized cortical volume; NAWM, normal appearing-white matter.

  • a The data are expressed as mean and SD. Volumes are expressed in milliliters. MTR values are expressed as percentage units. MD is expressed as mm2/s. Analysis of covariance, adjusted for age, sex, MS subtype, disability status, and use and duration of disease-modifying treatment, was used to explore the difference between patients with MS with and without comorbidities. The Benjamini-Hochberg correction was used to minimize the false discovery rate.

  • b Corrected P value < .05 was significant.